Results 211 to 220 of about 85,257 (242)
Some of the next articles are maybe not open access.

Bevacizumab for ROP

Ophthalmology, 2012
Michael, Blair, Michael J, Shapiro
openaire   +2 more sources

Bevacizumab

Reactions Weekly, 2023
openaire   +1 more source

Bevacizumab

Reactions Weekly, 2011
  +5 more sources

Bevacizumab

Reactions Weekly, 2013
  +4 more sources

Bevacizumab

Reactions Weekly
  +6 more sources

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Cancer Cell, 2021
Hai-Yan Tu, Tangfeng Lv, Shun Lu
exaly  

Bevacizumab

Reactions Weekly, 2012
  +4 more sources

Bevacizumab

Reactions Weekly, 2018
openaire   +2 more sources

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Annals of Oncology, 2023
C Lefeuvre-Plesse   +2 more
exaly  

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

European Journal of Cancer, 2023
Marianna Silletta   +2 more
exaly  
neoplasms
tumors
oncology
including cancer and carcinogens
glioblastoma
medicine general
ophthalmology
previous   20  21  22  23  24  25  

Home - About - Disclaimer - Privacy